罕见病药物氨己烯酸片是什么药

What are rare disease drugs? Vigabatrin tablets are used to treat partial epilepsy and infantile spasms.

The prevalence of epilepsy is 0.5%, 0.72% and 1.12% in developed, developing and underdeveloped countries respectively. The global average incidence of epilepsy is about 0.6%, one-third of which are refractory. General treatment methods include a combination of drugs, surgery, ketogenic diet, vagus nerve stimulation and other treatments. Vigabatrin's generic name is vigabatrin and its brand name is Sabril. It is a drug used to treat epilepsy and infantile spasms. It was developed in the 1980s. The treatment was approved in the UK in 1989. On August 21, 2009, the U.S. FDA approved Sabril as a monotherapy for pediatric patients 1 month to 2 years old, where the potential benefits of infantile spasms outweigh the potential risk of vision loss, and as an adjunctive (additional) treatment for adult patients with refractory complex partial epilepsy (CPS).

Clinical trials have shown that vigabatrin (vigabatrin) has a significant effect in treating epilepsy. However, this drug may also cause some side effects, such as drowsiness, reduced muscle tone, weight gain, insomnia, etc. However, its biggest disadvantage is its impact on visual field, and patients may suffer from irreversible concentric visual field defects. This side effect is more common in adult patients than in pediatric patients, with an incidence rate of approximately 25%–50% in adult patients, approximately 15% in pediatric patients, and approximately 15%–31% in infants and young children. The time from the start of treatment to the remission of epilepsy is about 12-35 days. The probability of visual impairment during this period is relatively low. It is currently believed that if Vigabatrin is used for more than 12 weeks and there is still no obvious effect, discontinuation of the drug can be considered.

Recommended related hot articles: /newsDetail/82880.html